Pharmaexcil wants WTO to take up UK ban issue

Published: 7-Jul-2014
Regulatory

Says MHRA ban of unlicensed herbal products in UK is violation of trade interest


Troubled by the plight of Ayurveda, Siddha and Unani (ASU) exporters in the wake of UK drug regulator the Medicines and Healthcare products Regulatory Agency's (MHRA) recent ban on the sale of unlicensed herbal products in UK, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) is seeking the intervention of the World Trade Organisation on this issue.

In a recent directive, the MHRA had stopped the immediate sale and use of all herbal medicines without registration or a product licence in Europe.

The Council has roundly condemned the stand taken by the MHRA, stating that the ban was 'a clear violation of trade interest', and a matter that the Commerce Ministry should bring to the attention of the WTO.

  • Companies:
  • MHRA
  • Pharmexcil
See more

You may also like

Regulatory

Biggest overhaul of trial regulation for 20 years

Read more
A series of new measures will be introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from partners

Trending Articles

  1. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  2. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  3. Tagrisso receives full approval in the EU For patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
  4. AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Lounges

23-25 April 2024 | Conference | Messe Karlsruhe, Germany See all

You may also like

Regulatory

Biggest overhaul of trial regulation for 20 years

A series of new measures will be introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from partners
Regulatory

MHRA joins international partnerships to set global standards for medicines and medical devices regulation

The UK is set to play a greater international role in making sure medicines and medical devices are regulated safely and efficiently worldwide, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced after being accepted as a full member of three international work-sharing partnerships
Regulatory

MHRA confirms registration of Avacta’s antigen lateral flow test

The company has ongoing commercial discussions with distributors and end user customers in countries that accept the CE mark for in vitro diagnostic products
Manufacturing

MHRA fully reinstates Bristol Labs GMP status

The company is now well-stocked for the shortages that may be brought about by Brexit
Regulatory

UK signs healthcare-focused Memorandum with Russia

The Medicines and Healthcare products Regulatory Agency has signed a Memorandum of Understanding with its Russian counterpart
Ingredients

Protak Scientific's enzymatic indicator gains MHRA support

The UK's Medicines and Healthcare products Regulatory Agency has agreed to form a focus group to discuss the use of enzymatic indicators for decontamination validation
Regulatory

UK clinical research post-Brexit

Dr Sheuli Porkess, Deputy Chief Scientific Officer of the ABPI here discusses the future of clinical research as the UK prepares to leave the EU
Subscribe now